Loading...
Market
Story
Scholar Rock ($SRRK) Shares Soar 200% After Apitegromab Succeeds in Phase 3 SAPPHIRE SMA Study
Oct 7, 2024, 11:15 AM
Scholar Rock (NASDAQ: $SRRK) announced topline results showing that its drug apitegromab met the primary endpoint in the late-stage Phase 3 SAPPHIRE study for treating patients with spinal muscular atrophy (SMA). The study demonstrated a statistically significant and clinically meaningful improvement in motor function among participants. Patients enrolled in the trial had been on either Evrysdi or Spinraza, existing treatments for SMA. The primary endpoint was achieved with a p-value of 0.019, with the 10 mg dose showing superior results. Following the positive trial results, Scholar Rock's stock soared more than 200%.
View original story
Similar markets
FDA approval • 25%
FDA rejection • 25%
Conditional approval • 25%
No decision • 25%
SMA Type 3 • 25%
SMA Type 2 • 25%
Both SMA Type 2 and 3 • 25%
Other • 25%
Europe • 25%
Asia • 25%
South America • 25%
Other • 25%
Approved in the US • 25%
Approved in the EU • 25%
Approved in both US and EU • 25%
Not approved • 25%
Phase 2 trial completion • 25%
Phase 3 trial initiation • 25%
Regulatory approval in any region • 25%
No significant milestone • 25%
Clinical hold • 25%
No action • 25%
Request for additional data • 25%
Other • 25%
BLA submission • 25%
Phase III trial initiation • 25%
Conditional approval • 25%
No progress • 25%
Yes • 50%
No • 50%
Alzheimer's drug • 25%
Multiple Sclerosis drug • 25%
Neuromuscular drug • 25%
Other • 25%